AstraZeneca’s Covid-19 vaccine accurately follows the genetic instructions programmed into AZD1222 by the developers to successfully provoke a strong immune response, according to a detailed analysis carried out by independent UK scientists.
Johnson & Johnson temporarily paused the company’s Covid-19 vaccine candidate clinical trials due to an unexplained illness in a study participant, delaying one of the highest-profile efforts to contain the global pandemic.
Days after Johnson & Johnson moved JNJ-78436735 into Phase III development, the company posted an interim analysis of a Phase I/IIa trial that showed a single dose of the novel coronavirus vaccine candidate induced a strong neutralizing antibody response in nearly all participants and was well-tolerated.
A lower supply of a certain type of immune cell in older people that is critical to fighting foreign invaders may help explain their vulnerability to severe Covid-19, scientists say. An antiseptic nasal spray containing povidone-iodine may help curb transmission of the new coronavirus, preliminary research suggests.
The U.S. National Institutes of Health launched a clinical trial of fostamatinib, currently used to treat a blood platelet-destroying autoimmune disorder, in patients hospitalized with severe Covid-19.
A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, the illness caused by the virus.
Moderna Inc. said an analysis of the early-stage data of the company’s experimental Covid-19 vaccine showed mRNA-1273 induced immune responses in older adults that were similar to younger participants.
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, the illness caused by the virus.
Novavax Inc.’s experimental Covid-19 vaccine produced high levels of antibodies against the novel coronavirus, according to initial data from a small, early-stage clinical trial, sending the company’s shares up 10%.